{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:33:30Z","timestamp":1790303610433,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["130423"],"award-info":[{"award-number":["130423"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"publisher","award":["3-847\/2013"],"award-info":[{"award-number":["3-847\/2013"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2013-03514"],"award-info":[{"award-number":["2013-03514"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.bbrc.2017.10.106","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T12:21:52Z","timestamp":1508761312000},"page":"477-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth"],"prefix":"10.1016","volume":"494","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-4604","authenticated-orcid":false,"given":"Tiago","family":"Pinheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Otrocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinton","family":"Seashore-Ludlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Rraklli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Forsberg-Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0920-5355","authenticated-orcid":false,"given":"Matthew","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2017.10.106_bib1","first-page":"726","article-title":"Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010","volume":"19","author":"Zhang","year":"2016","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.bbrc.2017.10.106_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11060-013-1338-5","article-title":"The role of cytotoxic chemotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline","volume":"118","author":"Olson","year":"2014","journal-title":"J.\u00a0Neurooncol"},{"key":"10.1016\/j.bbrc.2017.10.106_bib3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2017.10.106_bib4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.dnarep.2007.03.013","article-title":"MGMT hypermethylation: a prognostic foe, a predictive friend","volume":"6","author":"Jacinto","year":"2007","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bbrc.2017.10.106_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.mehy.2008.10.034","article-title":"New drugs for brain tumors? Insights from chemical probing of neural stem cells","volume":"72","author":"Diamandis","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbrc.2017.10.106_bib6","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1242\/dev.088005","article-title":"Neurotransmitter-mediated control of neurogenesis in the adult vertebrate brain","volume":"140","author":"a Berg","year":"2013","journal-title":"Development"},{"key":"10.1016\/j.bbrc.2017.10.106_bib7","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1210\/en.2010-0745","article-title":"Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance","volume":"151","author":"Rub\u00ed","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbrc.2017.10.106_bib8","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1158\/1535-7163.MCT-11-0268","article-title":"A\u00a0molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells","volume":"10","author":"Visnyei","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2017.10.106_bib9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2017.10.106_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ccell.2016.05.002","article-title":"Inhibition of dopamine receptor D4 impedes autophagic flux, proliferation, and survival of glioblastoma stem cells","volume":"29","author":"Dolma","year":"2016","journal-title":"Cancer Cell."},{"key":"10.1016\/j.bbrc.2017.10.106_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-6147(92)90025-2","article-title":"Molecular biology of dopamine receptors","volume":"13","author":"Sibley","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2017.10.106_bib12","article-title":"Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 ( DRD2 ) and epidermal growth factor receptor ( EGFR ) in glioblastoma","volume":"2","author":"Li","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2017.10.106_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11060-014-1688-7","article-title":"Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect","volume":"122","author":"Karpel-Massler","year":"2015","journal-title":"J.\u00a0Neurooncol"},{"key":"10.1016\/j.bbrc.2017.10.106_bib14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ebiom.2015.08.026","article-title":"The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes","volume":"2","author":"Xie","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrc.2017.10.106_bib15","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1073\/pnas.0712168105","article-title":"A\u00a0chemical method for fast and sensitive detection of DNA synthesis in\u00a0vivo","volume":"105","author":"Salic","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2017.10.106_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"key":"10.1016\/j.bbrc.2017.10.106_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/2211068215618869","article-title":"Precision cancer medicine in the acoustic dispensing era","volume":"21","author":"Kulesskiy","year":"2016","journal-title":"J.\u00a0Lab. Autom."},{"key":"10.1016\/j.bbrc.2017.10.106_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"Simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.bbrc.2017.10.106_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","article-title":"Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors","volume":"16","author":"Seeman","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbrc.2017.10.106_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/mol.114.096941","article-title":"Repurposing the antipsychotic trifluoperazine as an antimetastasis agent","volume":"87","author":"Pulkoski-Gross","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2017.10.106_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/emm.2004.50","article-title":"Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U87M G glioma cells","volume":"36","author":"Shin","year":"2004","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbrc.2017.10.106_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.MCT-16-0169-T","article-title":"Trifluoperazine, a well-known antipsychotic, inhibits glioblastoma invasion by binding to calmodulin and disinhibiting calcium release channel IP 3 R","volume":"16","author":"Kang","year":"2017","journal-title":"Mol. Cancer Ther."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17320843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17320843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T11:07:23Z","timestamp":1574939243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X17320843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":22,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0006291X17320843"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.10.106","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A chemical screen identifies trifluoperazine as an inhibitor of glioblastoma growth","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.10.106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}